Results 191 to 200 of about 6,366 (244)
Anthracyclines and Mitochondria
, 2011 Anthracyclines remain the cornerstone in the treatment of many malignancies including lymphomas, leukaemias, and sarcomas. Unfortunately, the clinical use of these potent chemotherapeutics is severely limited by the development of a progressive dose-dependent cardiomyopathy that irreversibly evolves toward congestive heart failure.
Mordente, Alvaro +4 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Medicinal Chemistry, 1998
This review summarizes the structure, the occurrence and the available data concerning the bioactivity of biosynthetic anthracyclines. The anthracyclines represent an important family of natural products produced by microorganisms of Streptomyces and related genera and include clinically useful agents for the medical treatment of human cancer.
Federico Arcamone
exaly +3 more sources
This review summarizes the structure, the occurrence and the available data concerning the bioactivity of biosynthetic anthracyclines. The anthracyclines represent an important family of natural products produced by microorganisms of Streptomyces and related genera and include clinically useful agents for the medical treatment of human cancer.
Federico Arcamone
exaly +3 more sources
Reactions Weekly, 2022 Archive of anthracyclines containing sub-folders named after each compound and its net charge. Every compound's folder contains a total of 20 files distributed into three sub-directories reporting QM (QM/), FF (FF/), and MD (MD ...
Giuliano Malloci (2060875) +5 more
openaire +2 more sources
Mitochondria as subcellular targets for clinically useful anthracyclines
Advanced Drug Delivery Reviews, 2001 Due to the widespread use of anthracyclines as antitumor agents, a large number of investigations have been reported analyzing clinical and molecular aspects of these quinone antibiotics.
Klaus Jung
exaly +1 more source
Acta Oncologica, 1989
The major limitation of the usefulness of anthracyclines is the development of drug resistance. Most of the data related to anthracycline resistance has been obtained in experimental animal tumors or in cultured human cell lines. An important characteristic obtained in these models is the common finding of cross-resistance to a series of drugs ...
Bhushan, Alok +3 more
openaire +4 more sources
The major limitation of the usefulness of anthracyclines is the development of drug resistance. Most of the data related to anthracycline resistance has been obtained in experimental animal tumors or in cultured human cell lines. An important characteristic obtained in these models is the common finding of cross-resistance to a series of drugs ...
Bhushan, Alok +3 more
openaire +4 more sources
International Journal of Oncology, 1996
The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line ...
G, Mazue +10 more
openaire +2 more sources
The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line ...
G, Mazue +10 more
openaire +2 more sources
Morpholinyl anthracyclines: Option for reversal of anthracycline resistance
European Journal of Cancer and Clinical Oncology, 1990Anthracyclines are potent chemotherapeutic drugs, consisting of a 4-ring aglycon and an aminosugar, which both can be substituted. The most widely used are doxorubicin and daunorubicin, the parent drugs. The efficacy, toxicity and drug resistance may be related to different parts of the anthracycline molecule.
de VRIES, Elisabeth GE, Zijlstra, Jan G
openaire +2 more sources
Expert Opinion on Drug Safety, 2006
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
Expert Opinion on Drug Safety, 2011
Anthracyclines are widely prescribed anticancer agents that cause a dose-related cardiotoxicity, often aggravated by nonanthracycline chemotherapeutics or new generation targeted drugs. Anthracycline cardiotoxicity may occur anytime in the life of cancer survivors.
Pierantonio, Menna +5 more
openaire +2 more sources
Anthracyclines are widely prescribed anticancer agents that cause a dose-related cardiotoxicity, often aggravated by nonanthracycline chemotherapeutics or new generation targeted drugs. Anthracycline cardiotoxicity may occur anytime in the life of cancer survivors.
Pierantonio, Menna +5 more
openaire +2 more sources
PHOTOINACTIVATION OF ANTHRACYCLINES*
Photochemistry and Photobiology, 1981Abstract— When adriamycin or daunomycin is irradiated at 366 nm, the drug loses its cytotoxic activity against Sarcoma 180 cells in culture. The half‐time for inactivation is about 9 h. Laboratory fluorescent lights also inactivate these anthracyclines with a half‐time of about one day.
Bruce A. Williams, Thomas R. Tritton
openaire +1 more source